Paclitaxel

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Paclitaxel
Oct 20, 2024, 19:52 | Blog
Stephen V Liu: Case report in Annals of Oncology of patients with NUT carcinoma responding to lurbinectedin
Stephen V Liu shared a post on X, about recent case report published in Annals…
Sep 17, 2024, 10:36 | Insight
Elisabetta Bonzano: First-line carboplatin-cyclophosphamid versus paclitaxel for mTNBC
Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X: “ First-line carboplatin-cyclophosphamid…
Aug 4, 2024, 05:15 | Insight
Yüksel Ürün: U.S. FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy
Yüksel Ürün shared on X: "U.S. FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy.…
Jul 29, 2024, 11:19 | Insight
Rasha Aboelhassan: We can give TDM1 in stage I HER2 positive breast cancer
Rasha Aboelhassan shared a post on LinkedIn about a recent paper by Paolo Tarantino et al., commenting:…
Jun 23, 2024, 04:42 | Drugs
Tanja Obradovich: This month marks Keytruda reaching 40 approved indications in the US
Tanja Obradovich shared on LinkedIn: “This month (as of June 17th) marks Keytruda reaching 40…
Jun 15, 2024, 12:39 | Insight
Docetaxel versus paclitaxel in black patients with breast cancer
The American Society of Clinical Oncology (ASCO) shared a post on X: “ICYMI from ASCO24:…
Jun 12, 2024, 15:34 | Insight
Piotr Wysocki: Dostarlimab combined with chemotherapy in dMMR/MSI-H advanced endometrial cancer patietns
Piotr Wysocki recently posted on LinkedIn: "Part 1 of the RUBY trial (NCT03981796) evaluated the…
Jun 12, 2024, 08:00 | Insight
Erman Akkus on a paper by Ruben Malmberg, et al.
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X: "Oral antihistamine…
Jun 5, 2024, 15:22 | Insight
Piotr Wysocki: T-DXd in metastatic ER+/HER2-low breast cancer patients after endocrine treatment failure
Piotr Wysocki recently posted on LinkedIn: "Results of a Destiny-Breast06 trial have been presented by…
Jun 5, 2024, 12:51 | Blog
Susan G. Komen: Tarah Ballinger presents results from the EAZ171 trial at ASCO24
Tarah Ballinger, Assistant Professor of Clinical Medicine at Indiana University School of Medicine, shared a…
May 18, 2024, 10:37 | Insight
Emad Shash: Our latest review on 'Prevention of Paclitaxel-Induced Peripheral Neuropathy'
Emad Shash, General Manager of the Breast Cancer Comprehensive Center of the National Cancer Institute,…
May 15, 2024, 13:45 | Blog
Sergio Cifuentes Canaval: Exciting insights from the MRI-guided optimization study in HER2+ breast cancer!
Sergio Cifuentes Canaval, Student Fellow at National Autonomous University of Mexico, shared a post on LinkedIn:…
Apr 8, 2024, 14:26 | Drugs
Dana-Farber’s Breast Oncology Center is leading a trial for stage 1 HER2+ Breast Cancer of T-DM1 followed by SQ trastuzumab versus TH
Dana-Farber’s Breast Oncology Center posted on X: "We are leading a randomized Phase 2 trial for…
Dec 12, 2023, 17:44 | Insight
Piotr Wysocki: SABCS2023 - Adjuvant chemoimmunotherapy does not benefit TNBC patients
Piotr Wysocki, Head of Department of Oncology at Jagiellonian University Hospital, shared on LinkedIn: "SABCS2023…
Sep 11, 2023, 00:27 | Insight
Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for Triple negative breast cancer is out in Molecular Cancer Therapeutics today. - Polyak Lab
All: 15 Posts: 1 - 100
Special Coverage